Genome Editing Market Top Driving Factors and Future Trends
The key factors propelling the growth of this genome editing market
are rising government funding and growth in the number of genomics
projects, high prevalence of infectious diseases and cancer,
technological advancements, increasing production of genetically
modified crops, and growing application areas of genomics.
According
to research report the global Genome Editing Market is projected to
reach USD 6.28 billion by 2022 from USD 3.19 billion in 2017, at a CAGR
of 14.5% during the forecast period.
Ask For Free PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=231037000
Some
of the major players in the genome editing market are Thermo Fisher
Scientific (US), Merck (Germany), Horizon Discovery Group (UK),
GenScript (US), Sangamo BioSciences (US), Integrated DNA Technologies
(US), Lonza Group (Switzerland), New England Biolabs (US), OriGene
Technologies (US), Transposagen Biopharmaceuticals (US), Editas Medicine
(US), and CRISPR Therapeutics (Switzerland).
Based on
technology, the genome engineering market is segmented into CRISPR,
TALEN, ZFN, antisense, and other technologies (PiggyBac, Flp-In, Adenine
Base Editor (ADE), and Jump-In). The CRISPR segment is expected to
register the highest growth during the forecast period. The ease of use
associated with the CRISPR technology is a significant advantage over
ZFN and TALEN, especially in generating a large set of vectors to target
numerous sites or even genome-wide libraries is one of the major
factors driving the growth of this segment.
The global genome
editing market, by application, is segmented into cell line engineering,
genetic engineering, and other applications (diagnostics and
therapeutics). The cell line engineering segment is estimated to
register the highest growth rate during the forecast period. Factors
such as increasing funding from governments and private organizations,
growing industry focus on stem cell research, and increasing global
awareness about stem cell therapies through various organizations are
driving the growth of the cell line engineering segment.
Based on
end user, the global genome engineering market is segmented into
biotechnology & pharmaceutical companies, academic & government
research institutes, and contract research organizations. The
biotechnology & pharmaceutical companies’ segment is estimated to
register the highest growth rate during the forecast period. The
increasing prevalence of infectious diseases and cancer are driving
research activities worldwide; this is expected to drive the demand for
genome editing in biotechnology & pharmaceutical companies.
In
2017, North America is projected to have the highest growth rate during
the forecast period. Factors such as the development of gene therapy in
the US, increasing use of genetically modified crops, rising prevalence
of infectious diseases and cancer, and rising availability of research
grants and funding are propelling market growth in North America.
Request Free Report Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=231037000
Comments
Post a Comment